| Stage | TW | % of rev | CME | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $585M | 100.00% | $1.7B | 100.00% | CME ×2.97 |
| Gross profit | $406M | 69.39% | $1.5B | 86.51% | CME +17.1pp |
| Operating income | $253M | 43.36% | $1.1B | 65.70% | CME +22.3pp |
| Pre-tax income | $290M | 49.61% | $1.4B | 77.98% | CME +28.4pp |
| Net income | $225M | 38.48% | $1.0B | 59.68% | CME +21.2pp |
| Stage | TW | CME | Gap · A − B |
|---|---|---|---|
| Revenue | $585M100.00% | $1.7B100.00% | CME ×2.97 |
| Gross profit | 69.39%$406M | 86.51%$1.5B | CME +17.1pp |
| Operating income | 43.36%$253M | 65.70%$1.1B | CME +22.3pp |
| Pre-tax income | 49.61%$290M | 77.98%$1.4B | CME +28.4pp |
| Net income |
| 38.48%$225M |
| 59.68%$1.0B |
| CME +21.2pp |
No shared counterparties.